206. 脆弱X症候群
[臨床試験数:98,薬物数:73(DrugBank:27),標的遺伝子数:46,標的パスウェイ数:57

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01325220
(ClinicalTrials.gov)
June 201128/3/2011Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X SyndromeA Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X SyndromeFragile X SyndromeDrug: arbaclofen;Drug: PlaceboSeaside Therapeutics, Inc.NULLCompleted5 Years11 YearsBoth172Phase 3United States
2NCT01282268
(ClinicalTrials.gov)
May 201120/1/2011Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X SyndromeA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X SyndromeFragile X SyndromeDrug: arbaclofen;Drug: placeboSeaside Therapeutics, Inc.NULLCompleted12 Years50 YearsBoth125Phase 3United States
3NCT01013480
(ClinicalTrials.gov)
November 200912/11/2009An Open Label Extension Study of STX209 in Subjects With Fragile X SyndromeAn Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X SyndromeFragile X SyndromeDrug: ArbaclofenSeaside Therapeutics, Inc.NULLTerminated6 Years40 YearsBoth45Phase 2United States
4NCT00892580
(ClinicalTrials.gov)
May 20091/5/2009Biomarker and DNA Collection in Subjects Participating in Protocol 22003Biomarker Testing and DNA Collection in Subjects Participating in an Open-Label, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Autism Spectrum DisordersFragile X SyndromeDrug: STX209Seaside Therapeutics, Inc.NULLCompleted6 Years17 YearsBoth32N/AUnited States
5NCT00823368
(ClinicalTrials.gov)
January 200913/1/2009Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001Biomarker Testing and DNA Collection in Subjects Participating in a Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X SyndromeFragile X SyndromeDrug: STX209Seaside Therapeutics, Inc.NULLCompleted6 Years40 YearsBothN/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00788073
(ClinicalTrials.gov)
November 20087/11/2008Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X SyndromeA Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X SyndromeFragile X SyndromeDrug: STX209;Drug: PlaceboSeaside Therapeutics, Inc.NULLCompleted6 Years40 YearsAll63Phase 2United States